Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000257737, designated as "novel transcript, antisense to STAB2," is a long non-coding RNA (lncRNA) locus transcribed antisense to the STAB2 (stabilin 2) gene. Natural antisense transcripts (NATs), such as this, are widespread in the human genome and can modulate gene expression through various mechanisms, including chromatin remodeling, transcriptional interference, and mRNA stability regulation. Studies suggest that antisense transcription in general may alter the chromatin environment and dynamics of sense transcript production, potentially buffering gene expression and histone acetylation states in a locus-specific manner. However, to date, there is no direct evidence or experimental characterization defining the function or clinical relevance of ENSG00000257737, and it is not considered a classical drug target. In summary, ENSG00000257737 is a long non-coding RNA annotated as antisense to the protein-coding gene STAB2, lacking evidence as a therapeutic target, with unclear biological and clinical significance.
Not applicable. No drugs or therapeutics target this entity.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to STAB2 (ENSG00000257737).